Overview

A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
0
Participant gender:
All
Summary
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Criteria
Inclusion Criteria:

- Histologically or cytologically confirmed advanced measurable or evaluable solid
tumors unresponsive to currently available therapies, or for which there is no
curative therapy

- Eastern Cooperative Oncology Group (ECOG) performance status 0 and 1

- Life expectancy more than12 weeks

- Adequate bone marrow, liver and renal function

Exclusion Criteria:

- Known brain metastasis

- Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of
start of screening procedures

- Major surgical procedure within 4 weeks of start of screening procedures

- Active bleeding disorder, including gastrointestinal bleeding, as evidenced by
hematemesis, significant hemoptysis or melena in the past 6 months